HC Wainwright & Co. Maintains Buy on InflaRx, Raises Price Target to $8

Benzinga Newsdesk www.benzinga.com Positive 72.3%

Neg 0% Neu 0% Pos 72.3%

HC Wainwright & Co. analyst Matthew Keller maintains InflaRx (NASDAQ:IFRX) with a Buy and raises the price target from $6 to $8.